McWilliams J E, Sanderson B J, Harris E L, Richert-Boe K E, Henner W D
Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland 97210-3098, USA.
Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):589-94.
The association between glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk has been controversial in the published literature. To examine this controversy, 12 case-control studies of GSTM1 status and lung cancer risk were identified in the published English literature. These studies included a total of 1593 cases and 2135 controls. We conclude that GSTM1 deficiency is a moderate risk factor for lung cancer development with an odds ratio of 1.41 (95% confidence interval = 1.23-1.61; P < 0.0001) by using Mantel-Haenszel methods for stratified analysis. This increased risk is evident for all the major histological subtypes of lung cancer. Although the increased risk is small, GSTM1 deficiency accounts for approximately 17% of lung cancer cases because of the high prevalence of GSTM1 deficiency.
谷胱甘肽S-转移酶M1（GSTM1）缺乏与肺癌风险之间的关联在已发表的文献中一直存在争议。为了探究这一争议，我们在已发表的英文文献中检索到12项关于GSTM1状态与肺癌风险的病例对照研究。这些研究总共纳入了1593例病例和2135例对照。我们得出结论，采用Mantel-Haenszel分层分析方法，GSTM1缺乏是肺癌发生的一个中度风险因素，优势比为1.41（95%置信区间=1.23-1.61；P<0.0001）。这种风险增加在肺癌的所有主要组织学亚型中都很明显。尽管风险增加幅度较小，但由于GSTM1缺乏的高患病率，GSTM1缺乏约占肺癌病例的17%。
